- Home
- AUTL vs DXYZ Comparison
AUTL vs DXYZ Comparison
Compare AUTL & DXYZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- DXYZ
- Stock Information
- Founded
- AUTL 2014
- DXYZ N/A
- Country
- AUTL United Kingdom
- DXYZ
- Employees
- AUTL N/A
- DXYZ N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- DXYZ
- Sector
- AUTL Health Care
- DXYZ
- Exchange
- AUTL Nasdaq
- DXYZ Nasdaq
- Market Cap
- AUTL 590.8M
- DXYZ 640.4M
- IPO Year
- AUTL 2018
- DXYZ 2024
- Fundamental
- Price
- AUTL $2.19
- DXYZ $61.28
- Analyst Decision
- AUTL Strong Buy
- DXYZ
- Analyst Count
- AUTL 3
- DXYZ 0
- Target Price
- AUTL $10.20
- DXYZ N/A
- AVG Volume (30 Days)
- AUTL 1.4M
- DXYZ N/A
- Earning Date
- AUTL 03-13-2025
- DXYZ N/A
- Dividend Yield
- AUTL N/A
- DXYZ N/A
- EPS Growth
- AUTL N/A
- DXYZ N/A
- EPS
- AUTL N/A
- DXYZ N/A
- Revenue
- AUTL $10,091,000.00
- DXYZ N/A
- Revenue This Year
- AUTL $851.83
- DXYZ N/A
- Revenue Next Year
- AUTL $264.18
- DXYZ N/A
- P/E Ratio
- AUTL N/A
- DXYZ N/A
- Revenue Growth
- AUTL 82.71
- DXYZ N/A
- 52 Week Low
- AUTL $2.07
- DXYZ N/A
- 52 Week High
- AUTL $7.37
- DXYZ N/A
- Technical
- Relative Strength Index (RSI)
- AUTL 37.25
- DXYZ N/A
- Support Level
- AUTL $2.18
- DXYZ N/A
- Resistance Level
- AUTL $2.38
- DXYZ N/A
- Average True Range (ATR)
- AUTL 0.16
- DXYZ 0.00
- MACD
- AUTL 0.01
- DXYZ 0.00
- Stochastic Oscillator
- AUTL 3.17
- DXYZ 0.00
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About DXYZ Destiny Tech100 Inc. Common Stock
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.